The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An exploratory study of 89Zr-DFO-Atezolizumab ImmunoPET/CT in patients with locally advanced or metastatic renal cell carcinoma.
 
I. Alex Bowman
Consulting or Advisory Role - Foundation Medicine
 
Marianna Dakanali
No Relationships to Disclose
 
Aditi Mulgaonkar
No Relationships to Disclose
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Corvus Pharmaceuticals; exelixis; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Xiankai Sun
No Relationships to Disclose
 
Orhan K. Oz
No Relationships to Disclose
 
James Brugarolas
Consulting or Advisory Role - Arrowhead Pharmaceuticals; Exelixis
Research Funding - Arrowhead Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent of HIF-2 biomarker (Inst); Patent pertaining HIF2a resistance mutations (Inst)
Travel, Accommodations, Expenses - Exelixis